Efficacy of single low dose rasburicase in management of Tumor Lysis Syndrome in leukaemia and lymphoma patients

Abstract Background Tumor lysis syndrome (TLS) is a metabolic emergency in hematology patients. Recommended dose of rasburicase for the management of TLS is 0.2 mg/kg/day for 5 days, which is cost prohibitive for many patients. Aim To determine the efficacy of single low dose rasburicase in prevention and treatment of hyperuricemia in TLS. Method ology: We planned a prospective study for safety and efficacy of fixed (weight based) dose of rasburicase to manage TLS. Patients diagnosed with leukemia/lymphoma with laboratory /clinical TLS or presence of ≥ 2 high risk factors and serum uric acid > 7.5 mg/dl were included. Primary end point was uric acid normalization ( Results 55 patients were recruited for this study. Paediatric patients ( Conclusion Single dose rasburicase with frequent laboratory monitoring is effective in management of TLS with significant reduction in financial toxicity.